Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-04-11
2006-04-11
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S548000, C514S569000
Reexamination Certificate
active
07026355
ABSTRACT:
The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.
REFERENCES:
patent: 4244968 (1981-01-01), Friedman
patent: 4346103 (1982-08-01), Friedman
patent: 4950687 (1990-08-01), Dall'Asta et al.
patent: 5652265 (1997-07-01), Vittori et al.
patent: 5986129 (1999-11-01), Di Napoli
patent: 6124358 (2000-09-01), Estanove et al.
patent: 6797727 (2004-09-01), Cruz et al.
patent: 0 809995 (2002-09-01), None
patent: WO 01/85201 (2001-11-01), None
patent: WO 02/058681 (2002-08-01), None
Remington's Pharmaceutical Sciences, 16thed., Osol et al. (eds.), published 1980 by Mack Publishing Co. (PA) p. 1855.
Webster's II New Riverside University Dictionary, published 1984 by Riverside Publishing Co (US), p. 614.
Webster's II New Riverside University Dictionary, published 1984 by Riverside Publishing Co (US), pp. 614 and 699.
Carney, SL, “Effects of Diacetyl Rhein on the Development of Experimental Osteoarthritis. A Biochemical Investigation”,Osteoarthritis Cartilage, 1996(4), pp. 251-261; 1996 Osteoarthritis Research Society.
Felisaz, N., et al., “Stimulating Effect of Diacerein on TGF-beta 1 and beta 2 Expressing in Articular Chondrocytes Cultered with and without Interleukin”,Osteoarthritis Cartilage, (1999)7, pp. 255-264; 1999 OcteoArthritis Research Society International.
French, M.H., et al., “Update on Radiation for Restensosis”, vol. 3 No. 1, pp. 1-6 (2002) Reviews of Cardiovascular Medicine.
Garas, S.M., et al., “Overview of Therapies for Prevention of Restenosis After Coronary Interventions”,Pharmacology and Therapeutics, 92 92001), pp. 165-178; 2001 Published by Elsevier Science Inc.
Kosco-Vilbois, M.H., “IL-18-a destabilizer of atherosclerotic disease”, TRENDS in Immunology, vol. 23, No. 3, Mar. 2002, p. 123, XP004338937.
Liistro, F., et al., “First Clinical experience with a Paclitaxel Derivate-Eluting Polymer Stent System Implantation for In-Stent Restenosis Immediate and Long-Term Clinical and Angiographic Outcome”, Received Jan. 10, 2002; revision received Mar. 1, 2002; accepted Mar. 6, 2002. From Catheterization Laboratories, Ospedale San Raffaele, and Emo Centro Cuore Columbus, Milan, Italy; pp. 1883-1886; 2002 American Heart Association, Inc.
Liu, Yanzhu et al., “Inhibiting effect of emodin and rhein on smooth muscle cells proliferation”, XP002219154, abstract, 1998.
Moldovan, F., et al., “Diacerhein and Rhein Reduce the ICE-induced IL-1beta and IL-18 Activation in Human Osteoarthritic Cartlage”, Osteoarthritis Cartilage, (2000) 8, pp. 186-196; 2000 OsteoArthritis Research Society International.
Moore, A.R., et al., “Effects of Diacerhein on Granuloma Induced Cartilage Breakdown in the Mouse”, Osteoarthritis Cartilage, (1998) 6, pp. 19-23; 1998 Osteoarthritis Research Society.
Pelletier, J.P., et al., “Efficacy and Safety of Diacerein in Osteoarthritis of the Knee: a Double-Blind, Placebo Controlled Trial”, Arthritis & Rheumatism, vol. 43, No. 10, Oct. 2000, pp 2339-2348; 2000 American College of Rheumatology.
Pietrangelo, A., et al. , “Diacerhein Blocks Iron Regulatory Protein Activation in Inflamed Human Monocytes”, Life Sciences, vol. 63 No. 14, pp. 213-219 (1998) Elsevier Science Inc.
Pujol, J.P., et al., “Effects of Diacerein on Biocynthesis Activities of Chondrocytes in Culture”, Biortheology, 37(2000), pp. 177-184; IOS Press.
Raines, E.W., “The Extracellular Matrix Can Regulate Vascular Cell Migration, Proliferation and Survival: Relationships to Vascular Disease”, 2000 Blackwell Science Ltd. Int. J. Exp. Path (2000) 81, pp. 173-182.
Schwartz, S.M., “Smooth Muscle Migration in Atherosclerosis and Restenosis”, J. Clin. Invest. The American Society for Clinical Investigation, Inc. vol. 99, No. 12, Jun. 1997, pp. 2814-2817.
Smith, G.N. et al., “Diacerhein Treatment Reduces the Severity of Osteoarthritis in the Canine Cruciate Deficiency Model of Osteoarthritis”, Arthritis & Rheumatism, vol. 42, No. 3, Mar. 1999, pp. 545-554; 1999 American College of Rheumatology.
Spencer, C.M. et al., “Diacerein”, Drugs 1997 Jan.: 53(1), pp. 93-106, Adis International Limited.
Tamura, T. et al., “Effects of Diacerein on Spontaneous Polyarthritis in Male New Zealand Black/KN Mice”, Osteoarthritis and Cartilage, (1999) 7, pp. 533-538; 1999 OsteoArthritis Research Society International.
Williams, D.O., “Intercoronary Brachytherapy: Past, Present and Future”, Circulation (2002), 105, pp. 2699-2700.
Cruz Tony
Pastrak Aleksandra
Fish & Richardson P.C.
Henley III Raymond J.
Transition Therapeutics Inc.
LandOfFree
Use of rhein or diacerhein compounds for the treatment or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of rhein or diacerhein compounds for the treatment or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of rhein or diacerhein compounds for the treatment or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532860